Falsified Medical Product Alert N°2/2019
ICLUSIG (ponatinib) 15mg and 45mg: falsified product alert
WHO issued this alert after Swiss health authorities reported on 15 January 2019 that a local wholesaler had bought falsified ICLUSIG 15mg. Investigation found two falsified versions traded globally, including through internet sales. Analysis found no ponatinib, and both contained paracetamol.1
- Issued
- 1 February 2019
- Issued by
- World Health Organization
- Name stated on packaging
- Packaging bears the ICLUSIG brand. WHO did not name the company shown on the falsified packs in the text.
- Genuine manufacturer's statement
- WHO said TAKEDA and INCYTE confirmed they did not manufacture or supply the products and that the batch numbers do not correspond to genuine records.
- Countries where detected
- Switzerland
Batches named in the alert
25A19E09 (15mg), PR072875 (45mg)
Advice as stated
Do not use the listed products. Anyone who has taken them or had an adverse event or lack of efficacy should seek advice from a health professional and report it to the national authorities. Obtain medical products only from authentic and reliable sources.
Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.
Sources
- World Health Organization, Medical Product Alert N°2/2019: Falsified ICLUSIG traded globally (1 February 2019)